We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: GLP-1 RA
MedXY News
EnglishTag

GLP-1 RA

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Predictors of Concurrent Endometrial Carcinoma in Minority Populations with Atypical Hyperplasia: A Synthesis of Clinical, Molecular, and Social Evidence
Clinical UpdatesAtypical HyperplasiaEndometrial Carcinoma

Predictors of Concurrent Endometrial Carcinoma in Minority Populations with Atypical Hyperplasia: A Synthesis of Clinical, Molecular, and Social Evidence

By MedXY|Jun 1, 2026

This review synthesizes recent evidence on concurrent endometrial carcinoma risk in atypical hyperplasia, highlighting significant disparities in minority populations, the protective role of adenomyosis, and the emergence of GLP-1 receptor

Glucagon-Like Peptide-1 Receptor Agonists and Vascular Protection: Mitigating Systemic and Ocular Risks in High-Risk Type 2 Diabetes
Clinical Updates
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
cardiovascular risk
GLP-1 RA

Glucagon-Like Peptide-1 Receptor Agonists and Vascular Protection: Mitigating Systemic and Ocular Risks in High-Risk Type 2 Diabetes

By MedXY|Apr 27, 2026

A large-scale cohort study demonstrates that GLP-1 RAs significantly reduce macrovascular and microvascular complications, including proliferative retinopathy and retinal vein occlusion, in patients with pre-existing diabetic retinopathy.

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management
CardiologyCagriSemaGLP-1 RA

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management

By MedXY|Feb 2, 2026

The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduct

Optimizing MASH Management: Synergistic Effects of Resmetirom, GLP-1 Receptor Agonists, and Weight Loss in the MAESTRO-NASH Secondary Analysis
Clinical Updatesclinical trialsGLP-1 RA

Optimizing MASH Management: Synergistic Effects of Resmetirom, GLP-1 Receptor Agonists, and Weight Loss in the MAESTRO-NASH Secondary Analysis

By MedXY|Jan 10, 2026

This review synthesizes findings from the MAESTRO-NASH trial, highlighting that Resmetirom’s efficacy is maintained alongside GLP-1 RAs and SGLT2 inhibitors, while being significantly enhanced by concurrent weight loss.

GLP-1 Receptor Agonists and Risk of GERD in Type 2 Diabetes: Clinical Implications from a Large Population-Based Cohort Study
Clinical UpdatesGERDGLP-1 RA

GLP-1 Receptor Agonists and Risk of GERD in Type 2 Diabetes: Clinical Implications from a Large Population-Based Cohort Study

By MedXY|Sep 30, 2025

GLP-1 receptor agonists modestly increase the risk of GERD and its complications compared to SGLT-2 inhibitors in type 2 diabetes patients, highlighting the need for vigilant symptom monitoring.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities